BI 1358894 DDI Study with Yasmin in Healthy Females

Phase 1, open-label, single-arm trial of bi 1358894 in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Ethinylestradiol at Steady State Over the Uniform Dosing Interval tau, Area Under the Concentration-time Curve of Drospirenone at Steady State Over the Uniform Dosing Interval tau and 2 more. Started Sep 2023; status: terminated.